Age and gender differences in the association between Nt-proBNP and glucometabolic disturbances
暂无分享,去创建一个
O. Melander | P. Nilsson | J. Malm | R. Willenheimer | C. Hall | M. Leósdóttir | S. Tjora
[1] V. Gudnason,et al. Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: a cross-sectional study. , 2010, American heart journal.
[2] M. Gheorghiade,et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. , 2009, Journal of cardiac failure.
[3] J. Januzzi,et al. Biology of the natriuretic peptides. , 2008, The American journal of cardiology.
[4] D. Levy,et al. Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals , 2007, Circulation.
[5] J. Rehfeld,et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. , 2006, European heart journal.
[6] M. Connock,et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. , 2006, The British journal of general practice : the journal of the Royal College of General Practitioners.
[7] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[8] M. Drazner,et al. Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study , 2005, Circulation.
[9] T. Marwick,et al. Determinants of subclinical diabetic heart disease , 2005, Diabetologia.
[10] A. DeMaria,et al. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. , 2004, American heart journal.
[11] P. Collinson,et al. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the ElecsysTM 1010 and 2010 analysers , 2004, Annals of clinical biochemistry.
[12] L. Groop,et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. , 2004, Diabetes care.
[13] S. Khouri,et al. A practical approach to the echocardiographic evaluation of diastolic function. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[14] D. Levy,et al. Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.
[15] N. Nikitin,et al. Application of Tissue Doppler Imaging in Cardiology , 2004, Cardiology.
[16] S. Mudaliar,et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.
[17] D. Levy,et al. Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function: Sex-Related Differences in the Framingham Heart Study , 2003, Circulation.
[18] D. Levy,et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.
[19] M. Jensen-Urstad,et al. Left ventricular diastolic function is related to glucose in a middle‐aged population , 2002, Journal of internal medicine.
[20] C. Otto,et al. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[21] K. Eriksson,et al. Long‐term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity , 2000, Journal of internal medicine.
[22] D. Levy,et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). , 1991, The American journal of cardiology.
[23] L. Truedsson,et al. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. , 2009, Acta medica Scandinavica.